BG104689A - Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system - Google Patents
Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous systemInfo
- Publication number
- BG104689A BG104689A BG104689A BG10468900A BG104689A BG 104689 A BG104689 A BG 104689A BG 104689 A BG104689 A BG 104689A BG 10468900 A BG10468900 A BG 10468900A BG 104689 A BG104689 A BG 104689A
- Authority
- BG
- Bulgaria
- Prior art keywords
- central nervous
- oestrogen
- transcription
- nervous system
- estradiol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Selected steroids are used to produce pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system (CNS) without influencing other organs or systems. These steroids are characterised in that they have a selective, neurotropic, oestrogen-like transcription effect, unlike the systematically active natural and synthetic oestrogens, including 17a-estradiol. It has been surprisingly discovered that the selected steroids, when used according to the invention, selectively influence the transcription of oestrogen-dependent genes in the central nervous system and cause alterations of the corresponding physiological parameters; have transcription effects specific to the central nervous systems in doses which have no biological effects on the tissues of the reproductive system; have transcription effects specific to the central nervous systems at doses at which neither 17b-estradiol nor 17a-estradiol have any effect, and do not influence the transcription of oestrogen-dependent genes in the central nervous system to a greater extent than the secondary 17b-estradiol. 3 claims
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19807264 | 1998-02-20 | ||
| DE1998121831 DE19821831A1 (en) | 1998-05-15 | 1998-05-15 | Selectively supplementing estrogen deficiency in the central nervous system, using 14,15-cyclopropano estrane steroid compounds |
| PCT/DE1999/000353 WO1999042108A1 (en) | 1998-02-20 | 1999-02-10 | Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104689A true BG104689A (en) | 2001-04-30 |
Family
ID=26044035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104689A BG104689A (en) | 1998-02-20 | 2000-08-15 | Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP1056460B1 (en) |
| JP (1) | JP2002503694A (en) |
| KR (1) | KR20010041107A (en) |
| CN (1) | CN1291102A (en) |
| AT (1) | ATE252388T1 (en) |
| AU (1) | AU739071C (en) |
| BG (1) | BG104689A (en) |
| BR (1) | BR9909205A (en) |
| CA (1) | CA2321498A1 (en) |
| CZ (1) | CZ291764B6 (en) |
| DE (1) | DE59907446D1 (en) |
| EA (1) | EA002707B1 (en) |
| EE (1) | EE03906B1 (en) |
| HU (1) | HUP0100742A3 (en) |
| ID (1) | ID27069A (en) |
| IL (1) | IL137727A0 (en) |
| IS (1) | IS5571A (en) |
| NO (1) | NO20004153L (en) |
| NZ (1) | NZ506049A (en) |
| PL (1) | PL342313A1 (en) |
| SK (1) | SK12152000A3 (en) |
| TR (1) | TR200002400T2 (en) |
| UA (1) | UA57830C2 (en) |
| WO (1) | WO1999042108A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1310799B1 (en) * | 2001-11-07 | 2005-12-21 | Schering AG | In vitro screening for ligands of the estrogen receptor |
| CN112189624A (en) * | 2020-09-08 | 2021-01-08 | 山东第一医科大学(山东省医学科学院) | Method for constructing and identifying female AD model by using receptor gene silencing technology |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
| US4897389A (en) * | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
| DE4239946C2 (en) * | 1992-11-27 | 2001-09-13 | Jenapharm Gmbh | Estrane derivatives with a 14alpha, 15alpha-methylene group and process for their preparation |
| US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
| DE4338314C1 (en) * | 1993-11-10 | 1995-03-30 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage |
| DE4429397C2 (en) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5 (10) -triene derivatives, processes for their preparation and pharmaceutical compositions containing these compounds |
| DE19524937A1 (en) * | 1995-07-08 | 1997-01-09 | Jenapharm Gmbh | Pharmaceutical preparations for the prophylaxis and therapy of radical-mediated cell damage and for drug substitution in men |
| JPH11510144A (en) * | 1995-07-24 | 1999-09-07 | ユニバーシティー・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド | Use of non-estrogenic polycyclic phenolic compounds for the manufacture of a medicament for imparting neuroprotection to cells |
-
1999
- 1999-02-10 TR TR2000/02400T patent/TR200002400T2/en unknown
- 1999-02-10 IL IL13772799A patent/IL137727A0/en unknown
- 1999-02-10 ID IDW20001592A patent/ID27069A/en unknown
- 1999-02-10 JP JP2000532123A patent/JP2002503694A/en not_active Abandoned
- 1999-02-10 DE DE59907446T patent/DE59907446D1/en not_active Expired - Fee Related
- 1999-02-10 EA EA200000858A patent/EA002707B1/en not_active IP Right Cessation
- 1999-02-10 CZ CZ20002938A patent/CZ291764B6/en not_active IP Right Cessation
- 1999-02-10 HU HU0100742A patent/HUP0100742A3/en unknown
- 1999-02-10 CN CN99803170A patent/CN1291102A/en active Pending
- 1999-02-10 PL PL99342313A patent/PL342313A1/en unknown
- 1999-02-10 BR BR9909205-0A patent/BR9909205A/en not_active IP Right Cessation
- 1999-02-10 AU AU29209/99A patent/AU739071C/en not_active Ceased
- 1999-02-10 AT AT99910118T patent/ATE252388T1/en not_active IP Right Cessation
- 1999-02-10 WO PCT/DE1999/000353 patent/WO1999042108A1/en not_active Application Discontinuation
- 1999-02-10 EE EEP200000477A patent/EE03906B1/en not_active IP Right Cessation
- 1999-02-10 SK SK1215-2000A patent/SK12152000A3/en unknown
- 1999-02-10 KR KR1020007009148A patent/KR20010041107A/en not_active Application Discontinuation
- 1999-02-10 EP EP99910118A patent/EP1056460B1/en not_active Expired - Lifetime
- 1999-02-10 NZ NZ506049A patent/NZ506049A/en unknown
- 1999-02-10 CA CA002321498A patent/CA2321498A1/en not_active Abandoned
- 1999-10-02 UA UA2000095399A patent/UA57830C2/en unknown
-
2000
- 2000-07-24 IS IS5571A patent/IS5571A/en unknown
- 2000-08-15 BG BG104689A patent/BG104689A/en unknown
- 2000-08-18 NO NO20004153A patent/NO20004153L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9909205A (en) | 2000-11-14 |
| CZ20002938A3 (en) | 2001-01-17 |
| NO20004153L (en) | 2000-10-09 |
| IS5571A (en) | 2000-07-24 |
| TR200002400T2 (en) | 2000-11-21 |
| CA2321498A1 (en) | 1999-08-26 |
| UA57830C2 (en) | 2003-07-15 |
| HUP0100742A3 (en) | 2002-07-29 |
| EA002707B1 (en) | 2002-08-29 |
| NO20004153D0 (en) | 2000-08-18 |
| PL342313A1 (en) | 2001-06-04 |
| WO1999042108A1 (en) | 1999-08-26 |
| ID27069A (en) | 2001-02-22 |
| AU739071C (en) | 2002-04-11 |
| EE200000477A (en) | 2001-12-17 |
| AU2920999A (en) | 1999-09-06 |
| EP1056460B1 (en) | 2003-10-22 |
| ATE252388T1 (en) | 2003-11-15 |
| JP2002503694A (en) | 2002-02-05 |
| EE03906B1 (en) | 2002-12-16 |
| HUP0100742A2 (en) | 2001-09-28 |
| KR20010041107A (en) | 2001-05-15 |
| EP1056460A1 (en) | 2000-12-06 |
| IL137727A0 (en) | 2001-10-31 |
| CZ291764B6 (en) | 2003-05-14 |
| DE59907446D1 (en) | 2003-11-27 |
| EA200000858A1 (en) | 2001-04-23 |
| AU739071B2 (en) | 2001-10-04 |
| NZ506049A (en) | 2002-09-27 |
| CN1291102A (en) | 2001-04-11 |
| SK12152000A3 (en) | 2001-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998027929A3 (en) | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder | |
| WO1996019568A3 (en) | Stabilized ribozyme analogs | |
| HUP0102483A2 (en) | Pharmaceutical compositions containing androst-5-ene-3betha,17betha-diol | |
| MX9700223A (en) | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension. | |
| PL323046A1 (en) | Procedures related to arterio-vascular and vascular transplants: method and compositions | |
| CA2337991A1 (en) | Benzocycloheptenes, process for their production, pharmaceutical preparations that contain the latter as well as their use for the production of pharmaceutical agents | |
| ATE235907T1 (en) | USE OF COMPETITIVE PROGESTERONE ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING | |
| NZ271363A (en) | Use of antiglucocorticoid steroids to treat anxiety disorders | |
| MY137435A (en) | Retinoid compounds (i) | |
| NZ333232A (en) | Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease | |
| BG102660A (en) | Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders | |
| BG104689A (en) | Pharmaceutical preparations for selectively supplementing oestrogen deficiency in the central nervous system | |
| GR3025872T3 (en) | Orally active derivatives of 1,3,5(10)-estratriene | |
| MX9800049A (en) | Mono- and disulfo-substituted anthraquinones and their use for the treatment of bone matrix disorders. | |
| EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
| WO1994024279A3 (en) | Agents for the prevention and treatment of huntington's disease and other neurological disorders | |
| AU8624198A (en) | 11beta-aryl substituted 14,17-ethano-oestratriens, method for the production of these compounds and their use in the production of medicaments. | |
| CA2421302A1 (en) | 4-halogenated 17-methylene steroids, method for the production thereof and pharmaceutical compositions containing these compounds | |
| ATE212352T1 (en) | UNSATURATED 14,15-CYCLOPROPANO-ANDROSTANES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | |
| Romanenkova | Regional demographic policy: goals, principles, possible solutions | |
| MX9800697A (en) | Use of calendula glycosides for the treatment of psoriasis. |